规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
Fisetin 可减少 3T3-L1 细胞中的脂质积累并降低 PPARγ 表达。 Fisetin 抑制前脂肪细胞发育的早期阶段并刺激 Sirt1 表达。 Fisetin 刺激 Sirt1 介导的 PPARγ 和 FoxO1 去乙酰化,增强 Sirt1 与 PPARγ 启动子的结合,从而降低 PPARγ 转录活性,从而抑制脂肪生成 [1]。非瑟酮结合微管蛋白并稳定微管,其结合特性明显优于紫杉醇。人前列腺癌细胞的非瑟酮处理导致微管相关蛋白 (MAP)-2 和 -4 大量过度表达。 Fisetin 强烈抑制 PCa 细胞的生长、迁移和侵袭。 Nudc 是一种与控制微管动力学的微管运动动力蛋白/动力蛋白复合物相关的蛋白质,可被 Fisetin 疗法抑制 [2]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
使用非瑟酮治疗可减少暴露于 UVB 射线的小鼠的炎症细胞浸润和增殖。此外,非瑟酮治疗还可降低 COX-2、PGE2 及其受体 (EP1-EP4) 等炎症介质的水平以及 MPO 活性。此外,非瑟酮还能降低暴露于 UVB 的皮肤中炎症细胞因子 TNFα、IL-1β 和 IL-6 的浓度。 p53 和 p21 蛋白表达的增加表明非瑟酮治疗还可以减少 DNA 损伤和细胞增殖标记物 [3]。
|
||
动物实验 |
|
||
参考文献 |
[1]. Kim SC, et al. Fisetin induces Sirt1 expression while inhibiting early adipogenesis in 3T3-L1 cells. Biochem Biophys Res Commun. 2015 Nov 27;467(4):638-44.
[2]. Mukhtar E, et al. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells. Cancer Lett. 2015 Oct 28;367(2):173-83 |
分子式 |
C15H10O6
|
|
---|---|---|
分子量 |
286.24
|
|
CAS号 |
528-48-3
|
|
相关CAS号 |
Fisetin quarterhydrate;Fisetin (Standard);528-48-3
|
|
SMILES |
O1C2C([H])=C(C([H])=C([H])C=2C(C(=C1C1C([H])=C([H])C(=C(C=1[H])O[H])O[H])O[H])=O)O[H]
|
|
InChi Key |
XHEFDIBZLJXQHF-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H
|
|
化学名 |
2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10 mg/mL (34.94 mM) in 45% PEG300 5% Tween-80 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL | |
5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL | |
10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06133634 | Recruiting | Dietary Supplement: Fisetin Other: Placebo |
Aging Endothelial Dysfunction |
University of Colorado, Boulder | September 25, 2023 | Phase 1 Phase 2 |
NCT05416515 | Recruiting | Drug: Fisetin | Carpal Tunnel Syndrome | Peter C. Amadio, M.D. | October 9, 2022 | Phase 2 |
NCT05595499 | Recruiting | Procedure: Biospecimen Collection Drug: Fisetin |
Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 |
Jonsson Comprehensive Cancer Center | March 27, 2023 | Phase 2 |
NCT04537299 | Active, not recruiting | Drug: Fisetin Drug: Placebo |
Covid19 SARS-CoV Infection |
Mayo Clinic | April 29, 2022 | Phase 2 |
Effect of fisetin on microtubule assembly in vitro. (A) Graph of microtubule polymerization in the presence of fisetin (10 μM), paclitaxel (10 μM), and control. Tubulin polymerization was measured by spectrophotometer at 340 nm every 1 min for 60 min. Data form a typical experiment performed three times with similar results. (B) Representative immunofluorescence photomicrographs of PC-3 cells incubated with DMSO (Control) and fisetin (80 μM) for 0, 30, 60, 90 minutes. The microtubule network was analyzed with the Nikon confocal system. Microtubule networks (green fluorescence), nuclei labeled with DAPI (blue fluorescence). Scale bars, 25 μm and 50 μM. Images are representative of three independent experiments. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) td> |
Fisetin and taxol interact within the β-tubulin binding pocket. (A) X-Ray co-crystal structure of β-tubulin and taxol. (B) Superimposition of taxol and of fisetin (both from X-ray structure and from docking calculation) onto the β-tubulin biding site. (C) Amino acid binding pocket of taxol on β-tubulin. (D–G) Representative view of taxol derived from X-ray. (E–H) Representative view of taxol derived from docking. (F–I) Representative view of fisetin on the amino acid binding pocket on β-tubulin domain. td> |
Effect of fisetin treatment on proteins associated with microtubule organization and cell cycle. (A–C) Representative blots showing the effect of fisetin treatment (0–80 μM) on α-tubulin acetylation, MT-associated proteins, and NudC protein respectively in PCa PC-3 and DU-145 cells. (D) The cell cycle distribution as analyzed by flow cytometry. PC-3 cells were treated with fisetin (0–80 μM) for 24 h. Data form a typical experiment performed three times with similar results. td> |